Virpax Pharmaceuticals, Inc.: Nasdaq/NYSE listing notice — Virpax receives Nasdaq delisting notice for bid price non-compliance

Virpax Pharmaceuticals, Inc.

Nasdaq notified Virpax on April 10, 2023 of non-compliance with Listing Rule 5550(a)(2) for bid price below $1.00.
Company has 180 calendar days, until October 9, 2023, to regain compliance by closing at $1.00+ for 10 consecutive days.
If not cured, Virpax may qualify for an additional 180-day period, subject to meeting other listing requirements and potential reverse stock split.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Virpax Pharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

April 10, 2023, Virpax Pharmaceuticals, Inc. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Bid Price Requirement”). The Notice does not result in the immediate delisting of the Company’s common stock from The Nasdaq Capital Market. The Nasdaq Listing Rules require listed securities to maintain a minimum bid pric

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001213900-23-029879

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.